Cellectar Biosciences, Inc. — Capital/Financing Update 2013

Feb 21, 2013

8-K 1 v335880_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: February 21, 2013

( Date of earliest event reported )

NOVELOS THERAPEUTICS, INC.

( Exact name of registrant as specified in its charter )

Delaware	333-119366	04-3321804
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification Number)

One Gateway Center, Suite 504

Newton, MA 02458

( Address of principal executive offices )

(617) 244-1616

( Registrant's telephone number, including area code )

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Field: Page; Sequence: 1

Field: /Page

ITEM 7.01 REGULATION FD DISCLOSURE

A copy of the press release issued by us on February 21, 2013 announcing the closing of the previously disclosed $5.5 million registered public offering of units consisting of our common stock and warrants to purchase our common stock is furnished as Exhibit 99.1 and is incorporated by reference.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number	Title
99.1	Press Release dated February 21, 2013 entitled “ Novelos Therapeutics Closes $5.5 Million Public Offering ”

Field: Page; Sequence: 2; Options: NewSection; Value: 2

2

Field: /Page

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 21, 2013
By:	/s/ Harry S. Palmin
	Name: Harry S. Palmin
	Title: President and Chief Executive Officer

Field: Page; Sequence: 3; Value: 2

3

Field: /Page

EXHIBIT INDEX

Number	Title
99.1	Press Release dated February 21, 2013 entitled “ Novelos Therapeutics Closes $5.5 Million Public Offering ”

Field: Page; Sequence: 4; Options: Last

4

Field: /Page